Eli Lilly and Company (LLY)
Eli Lilly's New Weight-Loss Treatment Shows Promising Results
An investigational drug developed by Eli Lilly delivered clinically meaningful weight loss in a trial, the company said as it looks expand its obesity treatment portfolio amid soaring demand.
Patients on Lilly's next-gen obesity drug lost 28% of body weight, company says
Eli Lilly said on Thursday that its experimental drug retatrutide helped patients diagnosed with obesity lose more than 28% of their weight over a year and a half in a key trial that helps pave the way for the firm to seek regulatory approval and launch the drug next year.
Eli Lilly says next-generation weight loss drug clears crucial obesity trial
Eli Lilly said its next-generation drug cleared a crucial late-stage trial in patients with obesity, delivering significant weight loss across doses. The results bring Lilly one step closer to filing for approval of the weekly injection, called retatrutide, which works differently from existing injections and pills.
Focus: Lower cost Novo, Lilly weight-loss pills draw patients from compounded drugs, doctors say
Lower prices for weight-loss pills from Novo Nordisk and Eli Lilly are prompting patients to switch from compounded medications to branded Wegovy and Foundayo, according to Reuters interviews with nine U.S. doctors.
Eli Lilly Is A Buy (Technical Analysis)
Eli Lilly exhibits strong bullish technicals, with price action, momentum, and relative strength all supporting a continued uptrend. Despite an 'F' valuation grade, LLY's growth, profitability, and upward earnings revisions reinforce its investment appeal. Recent earnings beat expectations, with Q1 EPS of $8.55 and revenue of $19.8B; 2026 guidance was raised.
Three Biotechs That Are Top Takeover Targets
Eli Lilly (NYSE:LLY | LLY Price Prediction) is the stock everyone wants to talk about, and the reasons are obvious: Mounjaro revenue jumped 125% to $8.66 billion last quarter, the company raised full-year revenue guidance to $82 to $85 billion, and the market cap now sits at roughly $881.8 billion.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Is Eli Lilly Going To $1,100?
Eli Lilly (NYSE:LLY | LLY Price Prediction) just delivered one of the most impressive quarters in big pharma history, and the stock is responding.
Eli Lilly launches Alzheimer's drug Donanemab in India
U.S.-based drugmaker Eli Lilly on Wednesday launched its Alzheimer's drug Lormalzi, also known as Donanemab, in India.
Eli Lilly Price Prediction: This Is Where The Stock Will End This Year
Few stocks have polarized investors in 2026 like Eli Lilly (NYSE:LLY | LLY Price Prediction).
Lilly Bounces Into ‘Sell in May' Territory as Pricing Pressures Loom
The market adage “Sell in May and Go Away” rarely fits a single name cleanly.
Why Eli Lilly (LLY) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
